13F filer · CIK 351051 ↗
Massachusetts Institute of Technology
You are looking at Q4 2020. See the latest, Q2 2026 →
Reported value
$89.2M
+98% on the quarter before
Positions
9
6 new · 3 sold out
Top 10
100.0%
of the value
Est. gain
+$24.2M
on stocks held all quarter
Est. return
+71.1%
on those stocks since Q3 2020
Positions as of Dec 31, 2020, from Massachusetts Institute of Technology's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2020. Striped tiles are options.
Largest buys
Since Q3 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Zoom~$24.1MNew · 0.0% → 27.0%+71,339 shares
- Dada Nexus Ltd~$3.2MNew · 0.0% → 3.5%+86,579 shares
- Adverum Biotechnologies Inc~$1.5MNew · 0.0% → 1.6%+134,154 shares
- Ocular Therapeutix Inc~$1.0MNew · 0.0% → 1.2%+50,396 shares
- Ribbon Communications Inc~$916,000New · 0.0% → 1.0%+139,568 shares
- Burning Rock Biotech Ltd~$349,000New · 0.0% → 0.4%+15,100 shares
- Apple~$91,805Added · 0.8% → 0.6%+692 shares
Largest sells
Since Q3 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Salesforce~$8.4MSold out · 18.6% → 0.0%−33,300 shares
- Crispr Therapeutics Ag~$1.9MSold out · 4.1% → 0.0%−22,162 shares
- Iveric Bio Inc~$870,000Sold out · 1.9% → 0.0%−154,269 shares
Holdings
As of Dec 31, 2020. Changes are in shares against Sep 30, 2020, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Boston Omaha CorpCOM · shares 0% · price +72.8% | 64.1% | $57.2M | +$24.1M | ||||||||
| ZoomCL A · shares New | 27.0% | $24.1M | — | ||||||||
| Dada Nexus LtdADS · shares New | 3.5% | $3.2M | — | ||||||||
| Adverum Biotechnologies IncCOM · shares New | 1.6% | $1.5M | — | ||||||||
| Ocular Therapeutix IncCOM · shares New | 1.2% | $1.0M | — | ||||||||
| Ribbon Communications IncCOM · shares New | 1.0% | $916,000 | — | ||||||||
| Textron IncCOM · shares 0% · price 0.0% | 0.59% | $527,000 | $0.00 | ||||||||
| AppleCOM · shares +23% · price +14.7% | 0.55% | $491,000 | +$51,195 | ||||||||
| Burning Rock Biotech LtdSPONSORED ADS · shares New | 0.39% | $349,000 | — | ||||||||
| Total · 9 positions | 100% | $89.2M | +$24.2M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2020 to Q4 2020: 3 stocks held throughout, up $24.2M (+71.1%).
- Boston Omaha Corp+$24.1M+73%
- Apple+$51,195+15%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | $732.6M+27% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $577.0M−23% | SEC ↗ |
| Q4 2025 | Feb 12, 2026 | $753.3M−18% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $920.4M−8% | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | $995.5M+41% | SEC ↗ |
| Q1 2025 | May 14, 2025 | $707.2M+0% | SEC ↗ |
| Q4 2024 | Feb 12, 2025 | $705.1M−6% | SEC ↗ |
| Q3 2024 | Nov 14, 2024 | $749.0M+17% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $638.9M+14% | SEC ↗ |
| Q1 2024 | May 14, 2024 | $558.2M+3% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $539.6M−7% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $581.2M−13% | SEC ↗ |
| Q2 2023 | Aug 14, 2023 | $669.2M+5% | SEC ↗ |
| Q1 2023 | May 4, 2023 | $639.6M+6% | SEC ↗ |
| Q4 2022 | Feb 10, 2023 | $602.4M+2% | SEC ↗ |
| Q3 2022 | Nov 3, 2022 | $588.0M+26% | SEC ↗ |
| Q2 2022 | Aug 12, 2022 | $466.3M−26% | SEC ↗ |
| Q1 2022 | May 13, 2022 | $626.9M−15% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $738.1M+727% | SEC ↗ |
| Q4 2020 | Feb 5, 2021 | $89.2M+98% | SEC ↗ |
| Q3 2020 | Nov 12, 2020 | $45.1M−34% | SEC ↗ |
| Q2 2020 | Aug 10, 2020 | $68.0M+52% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $44.8M−43% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $78.7M−16% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $94.2M−10% | SEC ↗ |
| Q2 2019 | Aug 9, 2019 | $104.4M−11% | SEC ↗ |
| Q1 2019 | May 14, 2019 | $117.6M+1% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $117.1M | SEC ↗ |